Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
EcoModular Advances EIC STEP Scale Up Application to Support European Manufacturing Expansion22.6.2026 09:55:00 CEST | Press release
AI-native robotics platform engages European innovation-funding specialist Catalyze to prepare its submission to the European Innovation Council's STEP Scale-Up programme, with its EU Manufacturing Hub as the anchor of a planned European scale-up DUBLIN, IE / ACCESS Newswire / June 22, 2026 / EcoModular, the AI-native robotics platform for volumetric manufacturing operated by Ascotway Limited and advancing a Nasdaq Capital Market direct listing, today announced that it has engaged Catalyze B.V., a leading European innovation-funding consultancy, to prepare and submit an application to the European Innovation Council (EIC) STEP Scale-Up programme. The application is being prepared for the programme's evaluation batch dated 9 September 2026. The EIC STEP Scale-Up programme forms part of the European Union's Strategic Technologies for Europe Platform (STEP) and is administered by the European Innovation Council. It is designed to provide investment support to European companies scaling st
Bear Robotics to Acquire Kinisi Robotics, Completing Its End-to-End Physical AI Robotics Platform22.6.2026 09:00:00 CEST | Press release
Kinisi adds the manipulation AI layer that completes Bear's multi-robot Physical AI platform - extending Bear's deployed fleet from moving and delivering to handling physical work itself. REDWOOD CITY, CA / ACCESS Newswire / June 22, 2026 / Bear Robotics today announced it has signed a definitive agreement to acquire Kinisi Robotics, in a transaction that will make Kinisi part of Bear. On closing, Kinisi's KR1 humanoid robot, its Bristol-based engineering team, and its Physical AI capabilities will be integrated into Bear Robotics, completing Bear's end-to-end Physical AI robotics platform. The transaction is expected to close in the coming days. Bear has built the world's most widely deployed fleet of service robots - more than 16,000 shipped into commercial service worldwide. Bear's robots already work together as one coordinated team through agentic multi-robot orchestration, moving freely through busy, changing spaces instead of following fixed tracks or routes. Most robotics compa
Ore Energy and Budget Thuis to Deploy 1 GWh of Multi-Day Iron-Air Energy Storage in a First for European Energy Suppliers22.6.2026 09:00:00 CEST | Press release
Dutch energy supplier commits to 1 GWh of iron-air energy storage to reduce consumer energy costs; First 400 MWh to be delivered in 2028 AMSTERDAM, NL / ACCESS Newswire / June 22, 2026 / Ore Energy, the Netherlands-based iron-air multi-day energy storage company, today announced an agreement with Budget Thuis, one of the largest Dutch energy suppliers, to deploy 1 GWh of iron-air long-duration energy storage (LDES). The agreement represents the largest iron-air energy storage offtake in continental Europe to date and the first with a European energy supplier. The agreement begins with a committed 400 MWh first phase planned for delivery in 2028. For Budget Thuis, the agreement is a strategic move to provide customers with more stable, affordable, and increasingly clean electricity as the Dutch power system becomes more dependent on wind energy. Ore Energy's multi-day storage technology is designed to store renewable electricity when it is abundant and dispatch it across extended low-re
Driving the World's Leading Supply Chains: 9 OMP Customers Named to The 2026 Gartner Top 2518.6.2026 15:00:00 CEST | Press release
As global leaders move from firefighting to foresight, OMP celebrates the enterprise visionaries scaling decision-driven intelligence at the speed of change. ANTWERPEN, BE / ACCESS Newswire / June 18, 2026 / OMP, a leading AI-powered provider of supply chain planning solutions, extends its congratulations to the 9 customer organizations recognized in the newly released Gartner® Supply Chain Top 25 and Masters for 2026. Now in its 22nd year, the Gartner Supply Chain Top 25 remains the definitive benchmark for supply chain excellence, evaluating global enterprises on financial performance, ESG initiatives, and community opinion. This year's rankings point to three capabilities separating market leaders: building an autonomous workforce where people and intelligent systems collaborate on decisions, adopting network-centric strategies that treat supply chain design as a continuous, adaptive process, and orchestrating decisions end-to-end across increasingly complex ecosystems. OMP's custom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom